Get started
Author

Chong Chyn Chua

Observed names: C. C. Chua, C. Chyn Chua, C.C. Chua, CHUA, CHONG CHYN, Chong C Chua, Chong C. Chua, Chua, Chong Chyn, Chyn C. Chua, Chyn Chua
Observed institutions: The University of Melbourne, Northern Health, Walter and Eliza Hall Institute of Medical Research, Austin Hospital, Monash Medical Centre, The Alfred Hospital, Northern Hospital, Centre for Eye Research Australia, Monash Health, Australasian Leukaemia and Lymphoma Group, Alfred Health, Austin Health, Monash University
ORCID: 0000-0002-2162-3288
Observed ORCID: 0000-0002-2162-3288
OpenAlex ID: A5041083418
Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML
2020 · C. D. DiNardo, I. S. Tiong, et al. · Blood · 708
PDF
Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined With Modified Intensive Chemotherapy
2020 · Chong Chyn Chua, Andrew W. Roberts, et al. · Journal of Clinical Oncology · 195
Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia
2022 · Donia M. Moujalled, Fiona C. Brown, et al. · Blood · 119
Phase Ib Study of the Anti-TIM-3 Antibody MBG453 in Combination with Decitabine in Patients with High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
2019 · Uma Borate, Jordi Esteve, et al. · Blood · 86
Treatment-free remission after ceasing venetoclax-based therapy in patients with acute myeloid leukemia
2022 · Chong Chyn Chua, Danielle Hammond, et al. · Blood Advances · 69
Targeting Molecular Measurable Residual Disease and Low-Blast Relapse in AML With Venetoclax and Low-Dose Cytarabine: A Prospective Phase II Study (VALDAC)
2024 · Ing Soo Tiong, Devendra K. Hiwase, et al. · Journal of Clinical Oncology · 35
American Society of Hematology 2025 guidelines for treating newly diagnosed acute myeloid leukemia in older adults
2025 · Mikkael A. Sekeres, Ryan Mattison, et al. · Blood Advances · 27
PDF
Venetoclax treatment in patients with cancer has limited impact on circulating T and NK cells
2022 · Charis E. Teh, Hongke Peng, et al. · Blood Advances · 23
PDF
Acquired Mutations in BAX Confer Resistance to BH3 Mimetics in Acute Myeloid Leukemia
2020 · Donia M Moujalled, Fiona C Brown, et al. · Blood · 22
Pretransplant MRD detection of fusion transcripts is strongly prognostic in KMT2A- rearranged acute myeloid leukemia
2024 · Sun Loo, Nicola Potter, et al. · Blood · 19
PDF
Peripheral blood stem cell mobilisation with G-CSF alone versus G-CSF and cyclophosphamide after bortezomib, cyclophosphamide and dexamethasone induction in multiple myeloma
2018 · Chong Chyn Chua, Hui Yin Lim, et al. · Bone Marrow Transplantation · 19
Retrospective review on isolated distal deep vein thrombosis (IDDVT) — A benign entity or not?
2016 · Prahlad Ho, Hui Y. Lim, et al. · Thrombosis Research · 19
AML-190: Anti-TIM-3 Antibody MBG453 in Combination with Hypomethylating Agents (HMAs) in Patients with High-Risk Myelodysplastic Syndrome (HR-MDS) and Acute Myeloid Leukemia: A Phase 1 Study
2020 · Andrew Brunner, Uma Borate, et al. · Clinical Lymphoma Myeloma & Leukemia · 18
Clinicopathological aspects of therapy-related acute myeloid leukemia and myelodysplastic syndrome
2019 · Chong Chyn Chua, Shaun Fleming, et al. · Best Practice & Research Clinical Haematology · 18
ALLG AMLM26 Phase 1B/2 Study Investigating Novel Therapies to Target Early Relapse and Clonal Evolution As Pre-Emptive Therapy in AML (INTERCEPT): A Multi-Arm, Precision-Based, Recursive, Platform Trial
2022 · Andrew H Wei, Harry J Iland, et al. · Blood · 17
Tranexamic acid versus placebo to prevent bleeding in patients with haematological malignancies and severe thrombocytopenia (TREATT): a randomised, double-blind, parallel, phase 3 superiority trial
2024 · Lise J Estcourt, Zoe K McQuilten, et al. · The Lancet Haematology · 16
Molecular Patterns of Response and Outcome in the Chemotherapy and Venetoclax in Elderly AML Trial (CAVEAT study)
2018 · Andrew H Wei, Chong Chyn Chua, et al. · Blood · 16
Retrospective evaluation of venous thromboembolism: Are all transient provoking events the same?
2017 · Chong Chyn Chua, Hui Yin Lim, et al. · European Journal Of Haematology · 15
Acquired BCL2 variants associated with venetoclax resistance in acute myeloid leukemia
2024 · Fiona C. Brown, Xin Wang, et al. · Blood Advances · 13
Single-cell Rapid Capture Hybridization sequencing reliably detects isoform usage and coding mutations in targeted genes
2025 · Hongke Peng, Jafar S. Jabbari, et al. · Genome Research · 12
PDF
Final analysis of the phase 1b Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT)
2025 · Chong Chyn Chua, Sun Loo, et al. · Blood Advances · 11
PDF
In Vivo Laser Confocal Microscopy Using the HRT-Rostock Cornea Module: Diversity and Diagnostic Implications in Patients with Uveitis
2017 · Lyndell L. Lim, Jing Xie, et al. · Ocular Immunology and Inflammation · 11
Revumenib As Pre-Emptive Therapy for Measurable Residual Disease in NPM1 mutated or KMT2A-rearranged Acute Myeloid Leukemia: A Domain of the Multi-Arm ALLG AMLM26 Intercept Platform Trial
2024 · Sun Loo, Harry Iland, et al. · Blood · 10
PDF
A physician targeted intervention improves prescribing in chronic heart failure in general medical units
2018 · Chong Chyn Chua, Anastasia Hutchinson, et al. · BMC Health Services Research · 10
PDF
Venous thromboembolism management in Northeast Melbourne: how does it compare to international guidelines and data?
2017 · Hui Y. Lim, Chong C. Chua, et al. · Internal Medicine Journal · 10
PDF
Works count: 77
Citation count: 1,644
H-index: 16
I10-index: 25
Year
Topic
Type